What changed, and when

Novartis Rhapsido (remibrutinib) goes “beyond CSU” with five AAAAI 2026 abstracts, spanning CSU analyses plus Phase II peanut allergy data, and signalling a planned Phase III food allergy program in H2 2026 (Novartis presents Rhapsido data at AAAAI).
Separately, Novartis reported a positive CHMP opinion for remibrutinib in CSU on 27 Feb 2026, indicating EU regulatory momentum alongside the AAAAI scientific push (Novartis receives positive CHMP opinion for remibrutinib in CSU).

60-second thesis frame

The decision hinge is whether remibrutinib’s BTK inhibition can be a repeatable “platform” across mast cell and IgE-driven disease, not just an oral alternative within CSU. On the plus side, Novartis is using AAAAI to link (a) durable CSU control signals from pivotal REMIX-1/2, to (b) a peanut allergy proof-of-concept that could justify a bigger Phase III bet in H2 2026, and (c) a broader urticaria runway (CIndU) already moving through late-stage development (Novartis presents Rhapsido data at AAAAI, Novartis remibrutinib first therapy to achieve Phase III primary endpoint in CIndU).
Confidence rises if peanut allergy efficacy is clinically meaningful on food-challenge outcomes and safety is clean enough for chronic use in otherwise healthy adults, and if payer friction in CSU remains manageable versus injectables. Confidence falls if food allergy effect sizes are modest, if bleeding or infection signals complicate risk tolerance, or if competitive standards of care (omalizumab, dupilumab, emerging anti-TSLP/anti-Siglec options) erode differentiation.

The seven diligence questions

Clinical

• In the Phase II peanut allergy study, what was the pre-specified primary endpoint (for example, challenge threshold), what was the responder definition, and how does the effect size compare to “real-world meaningful” protection against accidental exposure (Study of remibrutinib in peanut allergy, NCT05432388)?
• Across CSU REMIX-1/2, what is the speed of onset, depth of response at Week 12, and durability, and how do outcomes map to patient-relevant control metrics versus incumbent standards (REMIX-1, NCT05030311, REMIX-2, NCT05032157, Remibrutinib in Chronic Spontaneous Urticaria, NEJM)?

Payer or Access

• CSU: will US payers position an oral BTKi before or after biologics (omalizumab, dupilumab), and what prior auth logic is likely (step edits, duration requirements, specialist gatekeeping), given expected budget impact and chronic use? (Context on competitive set: Reuters on FDA approval and US pricing)
• Food allergy: if Phase III succeeds, what is the likely coverage framework (medical vs pharmacy benefit, integration with oral immunotherapy programs, specialist centers), and what outcomes will payers demand (reduced anaphylaxis claims, fewer ED visits, quality-of-life endpoints)?

Ops or Adoption

• What monitoring and contraindication story will clinicians accept for a covalent BTKi in largely non-life-threatening conditions, and how will Novartis message bleeding and infection risk in high-activity, pediatric-leaning allergy clinics (Novartis CHMP opinion release, safety summary context)?

Competitive

• Peanut allergy: what is the differentiation vs immunotherapy approaches and biologics being studied for food allergy, and is BTK inhibition best thought of as monotherapy, adjunct, or bridge-to-desensitization?

Team or Cap table

• Program risk: how tightly is remibrutinib tied to Novartis’ broader immunology and neuroscience R&D portfolio priorities (resource allocation, trial network leverage, lifecycle planning), and what internal trigger would cause Novartis to slow FA investment despite promising Phase II signals (Novartis presents Rhapsido data at AAAAI)?

Red flags

• Peanut allergy Phase II shows statistically positive but clinically marginal increases in challenge threshold, limiting payer willingness to reimburse a chronic systemic immunomodulator (trial endpoint framing: NCT05432388).
• Safety or tolerability profile becomes harder to defend in a generally healthy population (bleeding, infections, drug-drug interactions), raising “risk/benefit” objections for food allergy and mild-to-moderate disease.
• CIndU expansion stalls if subtype heterogeneity (dermographism, cold, cholinergic) produces uneven responses that complicate labeling and commercial focus (Novartis remibrutinib Phase III CIndU endpoint news).

Next catalyst

AAAAI 2026 (Philadelphia, 27 Feb–2 Mar 2026): the oral peanut allergy presentation and CSU posters are the nearest read-through, with an explicit Phase III food allergy start targeted for H2 2026 (Novartis presents Rhapsido data at AAAAI).

FAQ

• What exactly changed by Novartis’ Rhapsido (remibrutinib) data at AAAAI, and why does it matter for allergy markets?
  Novartis presented five AAAAI 2026 abstracts spanning CSU analyses plus Phase II data in IgE-mediated peanut allergy, positioning remibrutinib as potentially broader than CSU (Novartis presents Rhapsido data at AAAAI). The company also flagged that a Phase III food allergy program is planned for H2 2026, implying it sees a plausible development path if the Phase II signal holds (Novartis presents Rhapsido data at AAAAI).
• What is the clinical basis for the CSU story referenced in Novartis’ 23 Feb 2026 AAAAI announcement?
  The CSU program is anchored by REMIX-1 and REMIX-2, two global Phase III trials in patients symptomatic despite H1-antihistamines (REMIX-1, NCT05030311, REMIX-2, NCT05032157). Peer-reviewed publication reports significant improvement in a composite itching and hives measure at Week 12 with oral remibrutinib (Remibrutinib in Chronic Spontaneous Urticaria, NEJM).
• Which endpoints matter most for interpreting the peanut allergy data presented by Novartis at AAAAI 2026?
  The key is whether the study improves tolerance on double-blind, placebo-controlled food challenge style outcomes (challenge threshold and responder definitions), not just biomarkers (NCT05432388). A journal report associated with the peanut allergy work concludes the data support further development, but diligence should focus on magnitude, safety, and durability (JACI: Remibrutinib and peanut allergy).
• What is the regulatory path after Novartis’ AAAAI data announcement, and what are the next formal steps in the US and EU?
  In the US, Reuters reported FDA approval for Rhapsido in CSU on 30 Sep 2025, which frames remibrutinib as already commercial in at least one major market (Reuters on FDA approval). In the EU, Novartis stated CHMP issued a positive opinion on 27 Feb 2026, a key step that typically precedes a European Commission decision (Novartis CHMP opinion release).
• How could payer access shift after Novartis’ AAAAI 2026 remibrutinib announcement, especially in CSU?
  An oral option can be attractive operationally, but coverage will depend on positioning vs established injectables and total cost of care, including whether payers insist on step therapy or specialist prescribing (competitive context: Reuters on FDA approval and US pricing). If Novartis expands into food allergy, payers may demand evidence of real-world outcome improvements (fewer severe reactions, reduced ED use), not only increased challenge thresholds (endpoint framing: NCT05432388).

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 01 Mar 2026, 17:56 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Novartis; Rhapsido; remibrutinib; LOU064; Bruton’s tyrosine kinase; BTK inhibitor; chronic spontaneous urticaria; CSU; REMIX-1; NCT05030311; REMIX-2; NCT05032157; chronic inducible urticaria; CIndU; RemIND; symptomatic dermographism; cold urticaria; cholinergic urticaria; peanut allergy; IgE-mediated food allergy; NCT05432388; AAAAI 2026; CHMP; EMA; FDA; omalizumab; Xolair; dupilumab; Dupixent; H1-antihistamines; hidradenitis suppurativa

Find more Lucid Diligence Briefs here.